692 related articles for article (PubMed ID: 26075822)
1. shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model.
Zharikov AD; Cannon JR; Tapias V; Bai Q; Horowitz MP; Shah V; El Ayadi A; Hastings TG; Greenamyre JT; Burton EA
J Clin Invest; 2015 Jul; 125(7):2721-35. PubMed ID: 26075822
[TBL] [Abstract][Full Text] [Related]
2. Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration.
Zharikov A; Bai Q; De Miranda BR; Van Laar A; Greenamyre JT; Burton EA
Neurobiol Dis; 2019 May; 125():146-153. PubMed ID: 30658149
[TBL] [Abstract][Full Text] [Related]
3. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system.
Betarbet R; Canet-Aviles RM; Sherer TB; Mastroberardino PG; McLendon C; Kim JH; Lund S; Na HM; Taylor G; Bence NF; Kopito R; Seo BB; Yagi T; Yagi A; Klinefelter G; Cookson MR; Greenamyre JT
Neurobiol Dis; 2006 May; 22(2):404-20. PubMed ID: 16439141
[TBL] [Abstract][Full Text] [Related]
4. CNTNAP4 deficiency in dopaminergic neurons initiates parkinsonian phenotypes.
Zhang W; Zhou M; Lu W; Gong J; Gao F; Li Y; Xu X; Lin Y; Zhang X; Ding L; Zhang Z; Li G; Chen X; Sun X; Zhu X; Xu P; Zhang Y
Theranostics; 2020; 10(7):3000-3021. PubMed ID: 32194851
[No Abstract] [Full Text] [Related]
5. Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration.
Jimenez-Ferrer I; Jewett M; Tontanahal A; Romero-Ramos M; Swanberg M
Neurobiol Dis; 2017 Oct; 106():279-290. PubMed ID: 28736195
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.
Sherer TB; Kim JH; Betarbet R; Greenamyre JT
Exp Neurol; 2003 Jan; 179(1):9-16. PubMed ID: 12504863
[TBL] [Abstract][Full Text] [Related]
7. A highly reproducible rotenone model of Parkinson's disease.
Cannon JR; Tapias V; Na HM; Honick AS; Drolet RE; Greenamyre JT
Neurobiol Dis; 2009 May; 34(2):279-90. PubMed ID: 19385059
[TBL] [Abstract][Full Text] [Related]
8. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
[TBL] [Abstract][Full Text] [Related]
9. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
10. Interaction between subclinical doses of the Parkinson's disease associated gene, α-synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats.
Naughton C; O'Toole D; Kirik D; Dowd E
Behav Brain Res; 2017 Jan; 316():160-168. PubMed ID: 27585560
[TBL] [Abstract][Full Text] [Related]
11. α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism.
Yun SP; Kim D; Kim S; Kim S; Karuppagounder SS; Kwon SH; Lee S; Kam TI; Lee S; Ham S; Park JH; Dawson VL; Dawson TM; Lee Y; Ko HS
Mol Neurodegener; 2018 Jan; 13(1):1. PubMed ID: 29310663
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease.
Sanders LH; McCoy J; Hu X; Mastroberardino PG; Dickinson BC; Chang CJ; Chu CT; Van Houten B; Greenamyre JT
Neurobiol Dis; 2014 Oct; 70():214-23. PubMed ID: 24981012
[TBL] [Abstract][Full Text] [Related]
13. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
Tapias V; Cannon JR; Greenamyre JT
J Neurosci Res; 2010 Feb; 88(2):420-7. PubMed ID: 19681169
[TBL] [Abstract][Full Text] [Related]
14. Rotenone impairs autophagic flux and lysosomal functions in Parkinson's disease.
Wu F; Xu HD; Guan JJ; Hou YS; Gu JH; Zhen XC; Qin ZH
Neuroscience; 2015 Jan; 284():900-911. PubMed ID: 25446361
[TBL] [Abstract][Full Text] [Related]
15. Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone.
Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
Neuroscience; 2012 Feb; 203():170-9. PubMed ID: 22198020
[TBL] [Abstract][Full Text] [Related]
16. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
[TBL] [Abstract][Full Text] [Related]
18. Bilateral upregulation of α-synuclein expression in the mouse substantia nigra by intracranial rotenone treatment.
Carriere CH; Kang NH; Niles LP
Exp Toxicol Pathol; 2017 Feb; 69(2):109-114. PubMed ID: 27986376
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of alpha mangostin on rotenone induced toxicity in rat model of Parkinson's disease.
Parkhe A; Parekh P; Nalla LV; Sharma N; Sharma M; Gadepalli A; Kate A; Khairnar A
Neurosci Lett; 2020 Jan; 716():134652. PubMed ID: 31778768
[TBL] [Abstract][Full Text] [Related]
20. Chronic Systemic Exposure to Low-Dose Rotenone Induced Central and Peripheral Neuropathology and Motor Deficits in Mice: Reproducible Animal Model of Parkinson's Disease.
Miyazaki I; Isooka N; Imafuku F; Sun J; Kikuoka R; Furukawa C; Asanuma M
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32375371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
